[ Eloxx raises $24M in Series C ]
Eloxx has raised $24 million in Series C funding.
Founded in 2013, Eloxx is a Pontifax portfolio company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others.
This financing enables the company to initiate multiple clinical studies for EL-02, Eloxx’s lead compound.
|Founder / CEO||Silvia Noiman|